With the evolution of multiple novel treatment options in mCRPC, including novel hormonal agents and PARP inhibitors, as well as the emergence of novel therapeutic classes such as PSMA-targeted radioligand therapies, there is increasingly a wealth of options to offer patients. The PROMISE clinical-genomic platform can help to generate initial data on potential positive and negative predictive biomarkers to guide these types of therapeutic questions.

As treatment for prostate cancer is increasingly individualized and new biological subsets are identified through the increased use of NGS, it is also important to better define the natural history of these patient populations. The molecular characterization of exceptional responders and non-responders to standard of care therapies will help better define molecular predictive biomarkers. The improved understanding of molecularly defined subsets through hypothesis-generating retrospective studies can help improve the design of biomarker-driven clinical trials of prostate cancer.

Many studies focusing on characterizing the molecular alterations in prostate cancer have included a very limited number of ethnically diverse subsets of patients. Understanding how race and ethnicity impacts genomic profile and response to therapy is critical to bridging the disparities gap in men with prostate cancer. Real-world data from this platform can fill this gap.

The inclusion of underrepresented minorities in this dataset is one of the important missions of this consortium. Data from retrospective series can more extensively capture clinical outcomes and other information of more diverse populations, including minority populations underrepresented in clinical trials. The selection for this consortium of diverse clinical sites representing different geographic regions of the United States that serve unique underrepresented patient populations is an important step toward bridging the cancer genomics disparities gap in prostate cancer.